Pilot Study Of Redirected Autologous T Cells Engineered To Contain an Anti-BCMA scFv Coupled To TCRζ And 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2018
At a glance
- Drugs MTV-273 (Primary) ; Cyclophosphamide
- Indications Multiple myeloma
- Focus Adverse reactions
- 12 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 Sep 2020.
- 12 Oct 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.
- 24 Jan 2018 Planned End Date changed from 1 Sep 2019 to 1 Sep 2018.